Cargando…
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
Owing to their integral involvement in cell cycle regulation, the Polo-like kinase (Plk) family, particularly Plk1, has emerged as an attractive therapeutic target in oncology. In recent years, several Plk1 inhibitors have been developed, with some agents showing encouraging results in early-phase c...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335352/ https://www.ncbi.nlm.nih.gov/pubmed/25027517 http://dx.doi.org/10.1038/leu.2014.222 |